CoGenesis® Gastric
34-gene hereditary gastric cancer test
CoGenesis® Gastric is a 34-gene test for hereditary gastric cancers. It includes genes linked to a higher chance of developing gastric cancer: CDH1, BMPR1A, EPCAM, MLH1, MSH2, MSH6, PMS2, SMAD4, STK11 genes. It helps you understand your lifetime risk of developing gastric cancer.
- Individuals with personal or family history of gastric cancer, or those suspected of hereditary diffuse gastric cancer (HDGC)
- Identifying carriers of pathogenic variants in hereditary gastric cancer related genes
- Informing clinical management, including surveillance, preventive strategies
- Not intended as a diagnostic test for active cancer.
- Detecting non‑genetic or environmental causes of cancer
- Predicting exact age of onset or severity of disease
- Serving as a stand‑alone diagnostic tool without clinical correlation
2 sub-panels included:
| Step / Test | Accuracy | Notes |
|---|---|---|
| Variant calling – SNP | >99.9% | |
| Variant calling – Indel | >99% |
4mL peripheral blood (EDTA), 2mL saliva, 4 buccal swabs
Preferred sample type:
- 4mL Blood (EDTA tube),
- Codex-provided buccal swabs (4 swabs)
- Codex-provided saliva collection kit (2mL)
Saliva or buccal swab sample collection: Follow the enclosed instructions; do not eat, drink, or smoke for 30 minutes before collection.
- Insufficient DNA quantity or poor DNA quality
- Improperly labeled or contaminated samples
- Degraded specimens due to incorrect storage or transport
- Non-human samples or inappropriate specimen types
Samples must be collected and submitted by a licensed healthcare professional.
- Keep Blood samples at 4–8°C after collection; avoid freezing, deliver within 48 hours of collection.
- Saliva or buccal swabs are stability in room temperature for up to 7 days. Address: Unit 220, 2/F, Building 16W, HKSTP, Pak Shek Kok, NT, Hong Kong. Tel: +852 3008 2560
- Results may identify pathogenic, likely pathogenic, or variants of uncertain significance (VUS).
- Positive findings can inform risk‑reducing strategies and treatment options.
- Genetic counseling is recommended to help families understand implications.
Hereditary gastric cancers are often linked to mutations in genes responsible for cell adhesion, DNA repair, and tumor suppression. Among these, CDH1 mutations are strongly associated with Hereditary Diffuse Gastric Cancer (HDGC), a condition that significantly increases lifetime risk of developing aggressive gastric tumors. Other genes such as MLH1, MSH2, MSH6, PMS2 are involved in mismatch repair and are linked to Lynch syndrome, which predisposes individuals to gastric and other cancers. Genes like BMPR1A, SMAD4, STK11, and EPCAM are associated with polyposis syndromes and broader cancer predisposition. By analyzing 34 genes, CoGenesis® Gastric provides a comprehensive genetic profile that helps identify individuals at elevated risk. This information can guide clinical management, including enhanced surveillance, preventive interventions, and family risk assessment. Early identification of pathogenic variants enables proactive strategies to reduce cancer risk and improve long‑term outcomes.
— Kaurah P, Huntsman DG. GeneReviews® 2018.The survival rate of gastric cancer can be increased two-fold by early diagnosis.
Hong Kong-based molecular diagnostics laboratory specialising in clinical genomics, precision oncology, and rare disease diagnosis. Accredited to ISO 27001 and GenQA standards.
© 2026 Codex Genetics Limited. All rights reserved.
